Recent research has shown that blockade of the interaction between PD-L1 and PD-1 can enhance T cell function and facilitate antitumor activity, and various monoclonal antibodies against PD-1 and PD-L1 are in clinical trials for a variety of solid tumor types, including breast cancer, with encouraging activity in many cancers [5]. Here, PDCD1 is linked to breast carcinoma.